tradingkey.logo

MBX Biosciences announces equity offering after stock doubles

ReutersSep 22, 2025 8:34 PM

Shares of MBX Biosciences MBX.O down 3.8% in extended trading to $19.25 as it looks to capitalize on its surging stock by raising equity

MBX shares on Mon closed up 100% at $20 after co said its experimental drug, canvuparatide, met main goal in mid-stage trial for adults with chronic hypoparathyroidism, a hormone disorder that causes low calcium levels

After the bell, the Carmel, Indiana-based firm announces 10 million share offering

JP Morgan, Jefferies, TD Cowen and Guggenheim are joint bookrunners

Co went public last Sept after IPO of 10.2 mln shares priced at $16

With ~33.6 mln shares outstanding, co has about $672 mln market cap

All 7 analysts covering MBX are bullish with avg rating of 'strong buy"; median PT is $45, per LSEG data

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI